SCHEMBL30775258

SCHEMBL30775258

NC(=O)CN1CCC(Oc2ccccn2)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HTT P42858 1/20 0.48
KDM5A P29375 1/20 0.43
ALDH1A1 P00352 2/20 0.43
RET P07949 1/20 0.43
HCRTR1 O43613 1/20 0.43
HCRTR2 O43614 1/20 0.43
RAB9A P51151 1/20 0.42
RIPK1 Q13546 1/20 0.41
FURIN P09958 1/20 0.41
SCN9A Q15858 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
BTK Q06187 1/20 0.41
EGFR P00533 1/20 0.41
ERBB2 P04626 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
OPRK1 P41145 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775264 0.92 KDM5A (0.47) EPHX2MEN1KMT2AHTTKDM5A
SCHEMBL30775363 0.83 EPHX2 (0.44) EPHX2MEN1KMT2AHTTALDH1A1
SCHEMBL1306480 0.80 CARM1 (0.46) EPHX2KDM5ARAB9ASCN9A
SCHEMBL10819391 0.79 HRH3 (0.48) EPHX2KDM5ARETRIPK1SCN9A
SCHEMBL2763577 0.79 OPRK1 (0.56) EPHX2HRH3OPRK1
SCHEMBL5152829 0.78 EPHX2 (0.63) EPHX2KDM5AHCRTR1HCRTR2RIPK1
SCHEMBL30775237 0.77 CHRM2 (0.37) MEN1KMT2AHTTKDM5AEGFR
SCHEMBL30775358 0.77 EPHX2 (0.46) EPHX2ALDH1A1HRH3OPRK1
Hydrochloric Acid SCHEMBL23928369 0.77 EPHX2 (0.62) EPHX2KDM5AHCRTR1HCRTR2RIPK1
SCHEMBL5300149 0.77 ROCK1 (0.56) SCN9AHRH3OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR EPHX2 3020/4885MEN1 1984/4885KMT2A 4282/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR EPHX2 3020/4885MEN1 1984/4885KMT2A 4282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.